Literature DB >> 20450239

Implications of opioid analgesia for medically complicated patients.

Howard Smith1, Patricia Bruckenthal.   

Abstract

Opioid analgesics have an established role in the management of postoperative pain and cancer pain, and are gaining acceptance for the management of moderate to severe chronic noncancer pain, most notably chronic low back pain and osteoarthritis, that does not respond to other interventions. Many patients with chronic pain have co-morbid medical conditions that may complicate opioid therapy. Selecting the appropriate opioid requires knowledge of how individual opioids differ with respect to metabolism and interaction with concurrent medications, as well as the reasons why specific medical conditions may influence their efficacy and tolerability. Polypharmacy is a common complicating condition in the elderly and in patients with psychiatric illness, cancer, cardiovascular disease, diabetes mellitus or other chronic illnesses. Polypharmacy, though often necessary for patients with multiple medical conditions, also multiplies the risk of drug interactions. Pharmacokinetic drug interactions can increase or reduce exposure to the opioid or concurrent medications, reducing efficacy and/or tolerability and increasing toxicity. Pharmacodynamic interactions can enhance the depressive effects of opioids, compromising safety. Patients with impaired renal or hepatic function may have difficulty clearing or metabolizing opioids and concurrent medications, leading to increased risk of adverse events. Patients with cardiovascular, cerebrovascular or respiratory disease (including smokers of >/=2 packs/day with no other diagnosis) may be more susceptible to respiratory depression, bradycardia and hypotension with any opioid, and a few specific opioids pose additional risks. Patients with cerebrovascular disease, dementia, brain injury or psychiatric illness are more susceptible to opioid effects on the CNS, which can include euphoria, cognitive impairment and sedation. Appropriate opioid selection may mitigate these effects. Even in older patients, addiction, abuse and misdirection of prescribed opioids are of concern. Higher risk exists for patients with psychiatric illness, history of substance abuse, and identifiable substance abuse risk factors. Screening for abuse potential and vigilant patient monitoring should be routine. Opioids differ in their ability to produce euphoria, based on opioid receptor agonism, but substance abusers may be more influenced by availability, familiarity and cost factors. Consequently, opioid selection has limited influence on abuse potential but can facilitate ease of monitoring. This review provides an overview of opioid use in medically complicated patients and recommendations on how to optimize analgesia while avoiding adverse events and drug interactions in the clinical setting. Articles cited in this review were identified via a search of EMBASE and PubMed. Articles selected for inclusion discussed characteristics of specific opioids and general physiological aspects of opioid therapy in important patient populations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20450239     DOI: 10.2165/11536540-000000000-00000

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  126 in total

1.  Practice guidelines for chronic pain management. A report by the American Society of Anesthesiologists Task Force on Pain Management, Chronic Pain Section.

Authors: 
Journal:  Anesthesiology       Date:  1997-04       Impact factor: 7.892

2.  The effects of bolus administration of opioids on cerebrospinal fluid pressure in patients with supratentorial lesions.

Authors:  S Jamali; P Ravussin; D Archer; D Goutallier; F Parker; C Ecoffey
Journal:  Anesth Analg       Date:  1996-03       Impact factor: 5.108

3.  Palliative care in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).

Authors:  Paul A Kvale; Paul A Selecky; Udaya B S Prakash
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

4.  Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases.

Authors:  Li-Qun Yang; Shen-Jing Li; Yun-Fei Cao; Xiao-Bo Man; Wei-Feng Yu; Hong-Yang Wang; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

5.  The role of psychiatric disorders in predicting drug dependence treatment outcomes.

Authors:  Wilson M Compton; Linda B Cottler; Jacqueline L Jacobs; Arbi Ben-Abdallah; Edward L Spitznagel
Journal:  Am J Psychiatry       Date:  2003-05       Impact factor: 18.112

Review 6.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

7.  Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis.

Authors:  J P Haberer; P Schoeffler; E Couderc; P Duvaldestin
Journal:  Br J Anaesth       Date:  1982-12       Impact factor: 9.166

8.  Epidemiology of regular prescribed opioid use: results from a national, population-based survey.

Authors:  Teresa J Hudson; Mark J Edlund; Diane E Steffick; Shanti P Tripathi; Mark D Sullivan
Journal:  J Pain Symptom Manage       Date:  2008-07-10       Impact factor: 3.612

Review 9.  Basic pharmacology relevant to drug abuse assessment: tramadol as example.

Authors:  R B Raffa
Journal:  J Clin Pharm Ther       Date:  2008-04       Impact factor: 2.512

Review 10.  Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring.

Authors:  Shu-Feng Zhou; Charlie Changli Xue; Xue-Qing Yu; Chunguang Li; Guangji Wang
Journal:  Ther Drug Monit       Date:  2007-12       Impact factor: 3.681

View more
  20 in total

1.  Improving the Safety of Opioid Use for Acute Noncancer Pain in Hospitalized Adults: A Consensus Statement From the Society of Hospital Medicine.

Authors:  Shoshana J Herzig; Hilary J Mosher; Susan L Calcaterra; Anupam B Jena; Teryl K Nuckols
Journal:  J Hosp Med       Date:  2018-04       Impact factor: 2.960

2.  Treatment of chronic pain in older people: evidence-based choice of strong-acting opioids.

Authors:  Joseph V Pergolizzi
Journal:  Drugs Aging       Date:  2012-12       Impact factor: 3.923

Review 3.  The switch from buprenorphine to tapentadol: is it worth?

Authors:  Adriana Miclescu
Journal:  Rom J Anaesth Intensive Care       Date:  2016-10

4.  Persistent pain and frailty: a case for homeostenosis.

Authors:  Joseph W Shega; William Dale; Melissa Andrew; Judith Paice; Kenneth Rockwood; Debra K Weiner
Journal:  J Am Geriatr Soc       Date:  2011-12-08       Impact factor: 5.562

5.  Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States.

Authors:  Usama Jazzar; Shan Yong; Zachary Klaassen; Jinhai Huo; Byron D Hughes; Edgar Esparza; Hemalkumar B Mehta; Simon P Kim; Douglas S Tyler; Stephen J Freedland; Ashish M Kamat; Dwight V Wolf; Stephen B Williams
Journal:  Cancer       Date:  2018-04-16       Impact factor: 6.860

Review 6.  Treatment of chronic pain in older people: evidence-based choice of strong-acting opioids.

Authors:  Annette L van Ojik; Paul A F Jansen; Jacobus R B J Brouwers; Eric N van Roon
Journal:  Drugs Aging       Date:  2012-08-01       Impact factor: 3.923

7.  Opioid utilization patterns among medicare patients with diabetic peripheral neuropathy.

Authors:  Jacqueline Pesa; Roxanne Meyer; Tiffany P Quock; Stacy K Rattana; Samir H Mody
Journal:  Am Health Drug Benefits       Date:  2013-05

8.  Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers.

Authors:  Ziva D Cooper; Sandra D Comer; Margaret Haney
Journal:  Neuropsychopharmacology       Date:  2013-04-22       Impact factor: 7.853

Review 9.  Post-herpetic Neuralgia: a Review.

Authors:  Graham R Hadley; Julie A Gayle; Juan Ripoll; Mark R Jones; Charles E Argoff; Rachel J Kaye; Alan D Kaye
Journal:  Curr Pain Headache Rep       Date:  2016-03

10.  Preoperative administration of intramuscular dezocine reduces postoperative pain for laparoscopic cholecystectomy.

Authors:  Yaomin Zhu; Guixia Jing; Wei Yuan
Journal:  J Biomed Res       Date:  2011-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.